Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States, today announced that it has entered into an agreement with Canaccord Genutiy Corp. (the “Underwriter”), pursuant to which the Underwriter has agreed to purchase, on an underwritten basis, 4,100,000 subordinate voting shares of the Compay (the “Offered Securities”) at a price of C$24.50 per Offered Security, for aggregate gross proceeds to Trulieve of C$100,450,000.
The Offered Securities will be offered in each of the Provinces of Canada, other than Québec (the “Public Offering”) pursuant to a prospectus supplement to the Company’s base shelf prospectus dated May 14, 2019 (the “Prospectus”) and in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the “Concurrent U.S. Private Offering” and collectively with the Public Offering, the “Offering”). The Offered Securities may also be offered elsewhere on a private placement basis.
In addition, Trulieve has granted the Underwriter an over-allotment option (the “Over-Allotment Option”) to purchase up to an additional 615,000 Offered Securities on the same terms as the Offering, which Over-Allotment Option is exercisable in whole or in part, at any time and from time to time on or prior to the date that is 30 days following the closing of the Offering. If the Over-Allotment Option is exercised in full, the aggregate gross proceeds of the Offering will be C$115,517,500.
Net proceeds from the Offering are expected to be used primarily to fund Trulieve’s business development and for general working capital purposes.
Copies of the Prospectus, following filing thereof, may be obtained on SEDAR at www.sedar.com and from Canaccord Genuity Corp., 161 Bay Street, Suite 3000, Toronto, ON M5J 2S1. The Prospectus contains important detailed information about the Company and the Offering. Prospective investors should read the Prospectus and the other documents the Company has filed on SEDAR at www.sedar.com before making an investment decision.
Closing of the Offering is expected to occur on or about September 21, 2020 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange and the applicable securities regulatory authorities.
No securities regulatory authority has either approved or disapproved of the contents of this news release. The subordinate voting shares have not been and nor will they be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws. Accordingly, the subordinate voting shares may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Trulieve in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California, Massachusetts and Connecticut. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX Best Market under the symbol TCNNF. Learn more at: www.trulieve.com/